RxDoctor Payments DataLook up a doctor →

Karissa Boyd, DO

Hematology & Oncology · Columbus, MSNPI 1225135981

Payments from drug & device makers

$9,454in general payments, 2019–2025

Across 426 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Helsinn Healthcare SA$2K
  • Merck$686
  • Novartis$654
  • E.r. Squibb & Sons, L.L.C.$569
  • Pfizer$536
  • Gilead$414
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$7,68598%
  • Education$1262%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Helsinn Healthcare SA1$1,642
Merck34$686
Novartis35$654
E.r. Squibb & Sons, L.L.C.40$569
Pfizer34$536
Gilead(2 entities)20$414
Daiichi Sankyo Inc.16$354
Bristol Myers Squibb19$354
Johnson & Johnson18$352
Amgen15$281
Lilly USA, LLC12$230
Incyte Corporation11$213
AbbVie10$204
Exelixis Inc.11$175
Astellas Pharma US Inc10$173
GSK10$166
Jazz Pharmaceuticals Inc.6$157
Eisai Inc.10$155
Beigene USA, Inc.7$151
Pharmacosmos Therapeutics Inc.5$126
Boehringer Ingelheim7$124
AstraZeneca(2 entities)7$119
Adaptive Biotechnologies Corporation4$116
Puma Biotechnology, Inc.7$101
Array Biopharma Inc6$98
Seagen Inc.6$91
Stemline Therapeutics Inc.4$89
Boston Scientific1$87
Bayer4$74
Regeneron Healthcare Solutions, Inc.3$66
Grifols USA, LLC2$60
Takeda Pharmaceuticals U.S.A., Inc.4$58
Rigel Pharmaceuticals, Inc.3$50
Ipsen Biopharmaceuticals, Inc3$50
Global Blood Therapeutics, Inc.3$48
Sanofi3$48
Servier Pharmaceuticals LLC2$47
Tempus AI, Inc2$47
Morphosys, US Inc.3$45
Pharmacyclics LLC, An Abbvie Company3$42
Legend Biotech USA Inc.2$34
Taiho Oncology, Inc.2$31
Secura Bio, Inc.2$27
Helsinn Therapeutics (U.S.), Inc.2$27
Mirati Therapeutics, Inc.1$26
Blueprint Medicines Corporation2$25
Karyopharm Therapeutics Inc.1$24
ADC Therapeutics America, Inc.1$23
Pharmaessentia USA Corporation1$22
Beone Medicines USA, Inc.1$19
Apellis Pharmaceuticals, Inc.1$18
Genmab U.S., Inc.1$16
AVEO Pharmaceuticals, Inc.1$15
Agios Pharmaceuticals, Inc.1$15
EMD Serono, Inc.1$15
Geron Corporation1$14
Smith+Nephew1$14
Tesaro, Inc.1$14
Coherus Oncology, Inc.1$13
Acceleron Pharma, Inc.1$12

How this compares

$9,454 in reported general payments places this provider in the 35th percentile of 57 hematology & oncology providers in Mississippi.

See all hematology & oncology providers in Mississippi

Medicare billing

Part B allowed, 2024
$61,166
Medicare patients
211
Services billed
761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide17$204,467
XtandiEnzalutamide12$174,730
RevlimidLenalidomide12$145,763
EliquisApixaban60$44,644
Potassium Chloride76$3,464
Ondansetron OdtOndansetron45$484
Letrozole52$388
Levothyroxine Sodium49$386
Hydroxyurea31$382
Anastrozole34$344
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen50$308
Gabapentin42$287
Megestrol Acetate13$259
Bicalutamide12$225
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst14$171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$173$174,73012 claims
Bristol Myers SquibbRevlimid$354$145,76312 claims
PfizerEliquis$536$44,64460 claims
Lilly USA, LLCOlanzapine$230$5415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 57 hematology & oncology providers in Mississippi.

Other hematology & oncology in Columbus

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →